Navigation Links
SeqWright Continues Expansion of Next-Generation Sequencing Capabilities
Date:1/11/2011

HOUSTON, Jan. 11, 2011 /PRNewswire/ -- SeqWright Inc., a world-wide leader in custom genomic and molecular biology services, continues to make significant strides to position itself as the Next-Generation Sequencing Provider of choice for 2011. SeqWright's ongoing success can be attributed to the company's ability to respond quickly to customer's demands and by investing in key genomics technologies. Building on this success, SeqWright announced today the expansion of its Next-Generation Sequencing capacity by the acquisition of a second Illumina HiSeq 2000.

SeqWright has also expanded its bioinformatics capabilities with the acquisition of the PowerWulf GRaNDE Compute Engine from PSSC Labs, significantly increasing workflow. SeqWright's bioinformatics experts can map Next-Generation sequencing runs in under 24 hours, map multiple jobs at once, and map from multiple platforms simultaneously. This allows SeqWright to process more large-scale Next-Generation sequencing projects in less time, improving operational efficiency and increasing throughput. SeqWright's Next-Generation data management system, Isilon IQ, has also been augmented with increased storage and archiving tape capacity and a dedicated archiving server. These changes enhance SeqWright's regulatory compliance by meeting the back-up requirements of customers and regulatory agencies, consistent with SeqWright's focus on expanding its GLP and CLIA offerings.

With the Roche 454 GS FLX Titanium, AB SOLiD 4 and Illumina HiSeq 2000 Next-Generation Sequencing Platforms, an array of sequence capture and target enrichment technologies, and advanced data analysis and storage, SeqWright is positioned to offer the best solutions under one roof. SeqWright's Next-Generation services continue to expand and includes de Novo sequencing, SNP analysis (regulatory validated for the Roche 454 GS FLX Titanium), RNA and cancer genome sequencing. SeqWright continues to focus on offering project-specific solutions to its wide range of clients, from pharmaceutical companies to academia, while continuing to evaluate the market for the next advancement in the life science industry.

About SeqWright

Based in Houston, TX, SeqWright Incorporated is recognized as an international leader in the field of contract genomic services, including Next-Generation sequencing. For over sixteen years, SeqWright has provided state-of-the-art Molecular Biology and Genomic services, from small projects up to full clinical trials. SeqWright has received a license from the state of California to operate as a clinical laboratory. This license, along with its CLIA certification, allows SeqWright to handle clinical samples from the vast majority of the United States. For additional information about SeqWright and its services, please visit www.seqwright.com.


'/>"/>
SOURCE SeqWright Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SeqWright Announces the Addition of Illumina HiSeq 2000 to its Next Generation Sequencing Capabilities
2. SeqWright Expands Genomics Services Offering Through New Partnership With RainDance Technologies
3. SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma to Provide Next-Generation Hair Loss Treatment Genetic Testing
4. SeqWright to Invest in LaserGens Novel Lightning Terminators(TM)
5. California Grants SeqWright License to Operate as a Clinical Laboratory
6. Fourth Annual Probiotics Grant Continues to Fuel Growth In Research
7. IGEN Networks Corp continues to build a world class advisory board, with the appointment of three new members
8. Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation
9. New Test Centre in India: TUV Rheinland Continues Worldwide Investment Programme for Solar Industry
10. Simbionix Continues its Global Expansion
11. O2h Continues to Support Senexis to Support Patent Filing Senexis Limited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... Surface Plasmon Resonance (SPR) is ... optical phenomenon that is sensitive to changes in the dielectric properties of the medium ... changes in refractive index occurring up to 300 nm above the metal surface (Au) ...
(Date:2/28/2017)... 2017  Phosphorus, a computational genomics and clinical ... the Phosphorus Scientific Advisory Board, an established group ... the company on the development of new products ... visit http://phosphorus.com/about-us/ to learn more about ... gathered some of the top leaders in the ...
(Date:2/28/2017)... 28, 2017  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage ... treatment of autoimmune diseases, asthma and allergic diseases ... fourth quarter and full year ended December 31, ... recent business and clinical highlights. "During ... development pipeline by starting five clinical trials across ...
(Date:2/28/2017)... MA (PRWEB) , ... February 28, 2017 , ... ... clinical trials, yet requires extensive coordination and expertise. Colpitts Clinical Trial Travel ... celebrating 15 years of meeting this unique need within the biotechnology and pharmaceutical ...
Breaking Biology Technology:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):